• Acetylcholine is a major neurotransmitter in the brain1
  • In patients with AD, cholinergic neurons are progressively lost, reducing levels of acetylcholine1
  • ChEIs target cholinesterase enzymes (AChE and BuChE) and inhibit the breakdown of acetylcholine.1-3This increases the availability of acetylcholine at the cholinergic synapses.1,2
  • Currently available FDA-approved ChEIs for the treatment of mild, moderate and severe AD are donepezil, rivastigmine, and galantamine1

Acess our Slide Deck on Treatment principles of Alzheimer’s disease (AD) and learn more about treatment with cholinesterase inhibitors.

file_download Download in HQ
Latest review 10.11.2023
Published 17.11.2023
Permissions
Latest review 10.11.2023
Published 17.11.2023
Permissions

Related content

image Image A multi-arm, multi-stage platform trial illustration
A multi-arm, multi-stage platform trial illustration
29.04.2025 Alzheimer’s Disease
image Image Drug Delivery Systems to the Brain
Drug Delivery Systems to the Brain

Brain drug delivery systems, allied with their characteristics for overcoming the blood-brain barrier (BBB).

29.04.2025 Alzheimer’s Disease
image Image From One-Size-Fits-All to Precision Medicine
From One-Size-Fits-All to Precision Medicine

The use of a single treatment in heterogeneous populations has proved problematic in clinical trials undertaken in patients with neurodegenerative diseases.

29.04.2025 Alzheimer’s Disease